AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 213 min read$ABT

Abbott Laboratories (ABT) Plans Nutrition Spin-Off Amid Dividend

Abbott Laboratories (ABT) plans to spin off its Nutrition division, including brands like Similac, by the end of 2027. The move aims to unlock shareholder value, with the new entity to be led by Daniel Salvadori. Abbott's shares trade at a 24.5% discount to its GF Value of $135.69, offering a 2.59% dividend yield with a high payout ratio of 80%. The company reported better-than-expected Q3 2026 results but saw a slight share price dip post-announcement.

Original reporting
gurufocus.com
Published Oct 21, 2026, 12:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 1:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$ABT
Neutral
high confidence
Mentioned
$ABT
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ABTNeutralMed
01

Why it matters

The spin‑off separates a $8.5 B revenue business, creating a new publicly traded entity and a tax‑free distribution to shareholders, which may affect dividend sustainability and valuation metrics.

02

Market read

The announcement introduces a material corporate restructuring for a large‑cap dividend stock, likely influencing short‑term price action and long‑term valuation.

03

What to watch

Potential tax advantages for shareholders and the ability of the split entities to pursue focused growth strategies.

Relevance 7/10Novelty 8/10Timing: today

Background

Abbott Laboratories is a diversified healthcare company with a market cap of $177 B, known for its medical devices, diagnostics, pharmaceuticals, and Nutrition segment.

Company-level read

Ticker impact

$ABTNeutralHigh confidence
Context

Abbott announced a tax‑free spin‑off of its Nutrition division into a new public company by end‑2027.

Expected impact

likely modest downside as investors price in the upcoming dilution

Evidence & confidence

Shares already dipped on the announcement; the large $8.5 B division split is a material corporate action for a large‑cap stock.

Market effects

Sector

May prompt re‑valuation of other diversified healthcare firms with sizable non‑core units.

Regional

Limited to US healthcare sector; no broader regional effect.

Global

Minimal global impact beyond investors tracking large‑cap dividend stocks.

Counterpoint

What could challenge this read

The spin‑off could be a catalyst for a rally if the new Nutrition entity is valued higher than the current discount.

Key entities

  • company
    Abbott Laboratories

    US‑listed healthcare conglomerate (ticker ABT) announcing the spin‑off.

  • person
    Daniel Salvadori

    Appointed CEO of the new Nutrition spin‑off entity.

Read at source← All news

StoryAbbott to spin off Nutrition unit into independent public company by end‑2027

Also covered by

6 outlets

Related articles

OCT 21
$ABTHigh

Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027

Abbott Laboratories (ABT) plans to spin off its Nutrition division, generating $8.5B in annual revenue, into a separate publicly traded company by the end of 2027. The move, subject to approvals, will allow Abbott to focus on medical devices, diagnostics, and pharmaceuticals, with the new company led by Daniel Salvadori. Existing shareholders will receive shares in both entities, and the transaction is not expected to affect Abbott's 2026 or 2027 financial guidance.

finance.yahoo.com2 min
OCT 21
$ABTMed

Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits?

Abbott Laboratories (ABT) shares dropped 4% after announcing plans to spin off its Nutrition business, including Similac, by 2027. The unit generates $8.5B annually but has shown minimal growth. The move leaves Abbott with a medical device and diagnostics business, with $42B in annual sales. The company expects to maintain its 2026 guidance and current dividend payouts. Daniel Salvadori will lead the new nutrition company.

finance.yahoo.com2 min
OCT 21
$ABTHighAI 8/10

Abbott Laboratories Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

Abbott Laboratories reported Q3 2026 sales of $13.01B (up from $11.37B YoY) and net income of $920M (down from $1.64B YoY). Nine-month sales reached $36.77B (up from $32.87B YoY), with net income of $2.93B (down from $4.75B YoY). The company's products include vascular devices, diagnostic systems, nutrition products, and medicines, with sales distributed globally.

marketscreener.com2 min
OCT 21
$ABTHighAI 8/10

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

ABBOTT LABORATORIES (ABT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies • The new Nutrition company will be a gl

SEC EDGAR 8-K3 min
OCT 21
$ABTMed

Abbott to Carve Out Nutrition Business Into Independent Company -- 2nd Update

Abbott Laboratories plans to separate its nutrition business, with $8.5B in annual sales, into an independent company by 2027. The move aims to focus on higher-growth areas. Shares fell 4% premarket. Q3 sales rose 14% to $13.01B, but profit declined due to higher costs. Abbott faces ongoing litigation over its baby-formula facility and has agreed to multimillion-dollar settlements.

marketscreener.com2 min
OCT 21
$ABTMed

Abbott Plans to Spin Off Its Nutrition Business

Abbott plans to spin off its nutrition business, which generates $8.5bn in annual revenue, into an independent publicly traded company by the end of 2027. The move aims to allow both entities to focus on their respective markets. Abbott's remaining business will have $42bn in revenue and focus on medical devices, diagnostics, and pharmaceuticals. The transaction is subject to regulatory approvals and will not impact Abbott's 2026 and 2027 guidance.

marketscreener.com2 min